Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. - Test2 - elhamkhani - TriplyDB

Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia.

Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia.

http://www.wikidata.org/entity/Q33291387

about

Treatment for Barrett's oesophagus Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis Update on management of Barrett's esophagus Endoscopic options for treatment of dysplasia in Barrett's esophagus Early events during neoplastic progression in Barrett's esophagus Nanomaterials for photo-based diagnostic and therapeutic applications Interventional Therapy of Esophageal Cancer Treatment of GERD complications (Barrett's, peptic stricture) and extra-oesophageal syndromes.Adherence to therapy for Barrett's esophagus-associated neoplasia Cryospray ablation using pressurized CO2 for ablation of Barrett's esophagus with early neoplasia: early termination of a prospective series.A randomised controlled trial of ALA vs. Photofrin photodynamic therapy for high-grade dysplasia arising in Barrett's oesophagus.Photodynamic therapy using 5-aminolaevulinic acid for the treatment of dysplasia in Barrett's oesophagus.Hexylether derivative of pyropheophorbide-a (HPPH) on conjugating with 3gadolinium(III) aminobenzyldiethylenetriaminepentaacetic acid shows potential for in vivo tumor imaging (MR, Fluorescence) and photodynamic therapy Image cytometry accurately detects DNA ploidy abnormalities and predicts late relapse to high-grade dysplasia and adenocarcinoma in Barrett's oesophagus following photodynamic therapy.Low grade dysplasia in Barrett's esophagus: Should we worry?Upregulation of mucin glycoprotein MUC1 in the progression to esophageal adenocarcinoma and therapeutic potential with a targeted photoactive antibody-drug conjugate Endoscopic treatments for Barrett's esophagus: a systematic review of safety and effectiveness compared to esophagectomy.Depth of submucosal invasion does not predict lymph node metastasis and survival of patients with esophageal carcinoma History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus.Biomarkers in Barrett's Esophagus.Comparison of nuclear texture analysis and image cytometric DNA analysis for the assessment of dysplasia in Barrett's oesophagus.Ablative therapy for esophageal dysplasia and early malignancy: focus on RFA.Barrett's oesophagus: Evidence from the current meta-analyses.Medical and endoscopic management of high-grade dysplasia in Barrett's esophagus Management of Barrett's oesophagus.Esophageal resection for high-grade dysplasia and intramucosal carcinoma: When and how?Photodynamic therapy (PDT) using HPPH for the treatment of precancerous lesions associated with Barrett's esophagus.Safety assessment of oral photodynamic therapy in rats.Endoscopic ablation therapy for gastrointestinal superficial neoplasia.The pharmacokinetics and safety of porfimer after repeated administration 30-45 days apart to patients undergoing photodynamic therapy.Prevalence and predictors of recurrent neoplasia after ablation of Barrett's esophagus Endoscopic management of Barrett's esophagus: advances in endoscopic techniques.British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus.Barrett's esophagus and the increasing role of endoluminal therapy.Preference of endoscopic ablation over medical prevention of esophageal adenocarcinoma by patients with Barrett's esophagus Photodynamic therapy for photochemists.The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis.Current surveillance and therapeutic options for barrett esophagus Prediction of response to endoscopic therapy of Barrett's dysplasia by using genetic biomarkers.Treatment of Barrett's esophagus with high-grade dysplasia or cancer: predictors of surgical versus endoscopic therapy.

P2860

Q24240701-E072E7A6-830D-4AFA-817B-046B32A5C127 Q24602426-C8DBD52A-FD43-4D8A-82F8-261A5AC656EE Q26751160-3BBB26A1-ACF0-4BE1-944F-7BF87262F244 Q26771415-14CBC3DC-7322-4549-8E5C-7A1696578AF3 Q26825349-A61D2857-0152-4D8C-9CE6-F79D5A4B5C4C Q27013549-DFB9CD19-1E0E-489E-9880-B68704718BA9 Q28072495-E311EF3F-8A8C-4283-BC77-454130EE32C8 Q30472472-6BEF491D-91A7-442D-991A-38EFA3BE9FA4 Q30489067-2AB45EE6-E0BA-4805-B58C-7A32114AF3CB Q30655266-D51D3A1B-CF79-46CD-9C83-F7768FBE46D0 Q31065106-5BD2575C-864C-4B9C-8D56-0E810EA7A0EE Q33324158-21EF1BD1-165F-4573-B9BB-533111249323 Q33553797-91A556F5-FB04-49A4-AA93-3D259140B673 Q33575943-877799FC-7DE3-478A-8669-C0543637C9CF Q33628118-741CE3B9-BB8C-42FB-A6E6-69453F8F5A4E Q33648759-0D02C8BE-CC43-4A69-A043-1A10BF95688D Q33704510-0904F40C-C86D-477E-AB03-73FB583D18A8 Q33712556-5A12989A-F99F-40F3-9C7B-3BB15BA129A7 Q33786336-E8E6FE45-8B56-4D40-8825-FF974960CAF4 Q34011000-239F3785-D6D7-4530-A74D-E13C5DCF3D95 Q34024948-1A1BBA80-87DA-4F20-8AB2-5A47EC7596EC Q34029709-9F10686E-2A03-4106-B551-35F87741A8E2 Q34047978-51492E92-A265-44F8-B74C-964AAA84B17F Q34050233-7C4507A0-E923-42D0-AF02-C8FC0B853589 Q34062414-D5ED14FE-8DCF-4651-812D-AADB646E80DE Q34063704-8ED93241-41F8-4B08-BFAA-0E18F7C3EFFA Q34068196-2F8E2777-35E6-459A-B10A-06F8D2F1E5B2 Q34216350-EF5D6DBC-1153-4EC1-89AA-54215CF924E5 Q34234245-D5CC7B67-B1E2-48B1-B4B6-628B0E5EE63B Q34296675-73DB0E95-8098-47F3-9F2B-AE382000225B Q34309843-94F99C3B-C7EA-4F40-85B5-D6D941B794DB Q34325283-C490B162-B84D-4E64-8DCC-7B22FD43BDFA Q34380645-CF5E2E66-9FFB-43BE-A175-1529547836EC Q34408906-2A841C30-CD29-4BDF-9E0A-8FFEF44D6064 Q34490562-84DE1856-7400-4079-B899-3D235765E6C5 Q34775481-F473E578-0044-4000-8606-2F72E520B993 Q34786281-FA6E9D61-61A8-44EC-974D-FA86B05D147C Q34933738-128F7A45-994A-4357-9BA6-74E39FDE3F17 Q35031044-C5A5B5C8-4F23-46A8-A298-4129D7FE61FC Q35040670-EEF258E5-33E8-4CED-8C80-EB0E322E940D

P2860

Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia.

http://www.wikidata.org/entity/Q33291387

description

2007 nî lūn-bûn

@nan

2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Five-year efficacy and safety ...... arrett's high-grade dysplasia.

@ast

Five-year efficacy and safety ...... arrett's high-grade dysplasia.

@en

Five-year efficacy and safety ...... arrett's high-grade dysplasia.

@nl

type

label

Five-year efficacy and safety ...... arrett's high-grade dysplasia.

@ast

Five-year efficacy and safety ...... arrett's high-grade dysplasia.

@en

Five-year efficacy and safety ...... arrett's high-grade dysplasia.

@nl

prefLabel

Five-year efficacy and safety ...... arrett's high-grade dysplasia.

@ast

Five-year efficacy and safety ...... arrett's high-grade dysplasia.

@en

Five-year efficacy and safety ...... arrett's high-grade dysplasia.

@nl

P1433

Q33291387-EE7088D4-8BD5-4E7D-8915-FD2D714C3353

P1476

Q33291387-AFA62381-2492-484C-AC1F-9C9172911F6E

P2093

Q33291387-0B8A1639-6B80-41D5-BB47-9C1B6269F837

Q33291387-187FFE1C-3AFE-4BEC-ADD5-10DE80096E44

Q33291387-29B42989-C14F-4D73-834B-F60EF940C10D

Q33291387-515C356E-D4B8-4591-8D8E-FCC757C056D3

Q33291387-51EC914A-00A6-4905-BF5F-7D18C2D5E8B3

Q33291387-56F54E5B-DCB0-47E9-9337-8EF5C89BDB92

Q33291387-5B21B95E-89F1-4CAC-B286-896C2AD6D245

Q33291387-8D157B1C-B079-447F-959E-1CC7B49FBE9F

Q33291387-A15907CE-C3E4-4E82-86EB-27F7677062D7

Q33291387-AB92D3FF-4172-43EE-AE5C-6CDAA6CB30B0

P304

Q33291387-4D184521-A6E1-450B-9B26-A62F248803A2

P31

Q33291387-038CCBEC-980D-4E1F-A27A-4C43447927F4

P356

Q33291387-421800DB-6DB8-4170-84F7-B8FFB8BC6C09

P407

Q33291387-216F20FC-7553-46FC-87A9-5D05083B8A18

P433

Q33291387-7B100100-1C1A-428F-896D-C7FFC6C59AB8

P478

Q33291387-D9E40677-AD4C-43D1-AC68-BE62B9662C20

P577

Q33291387-FC4F06E7-3A55-489F-8634-6B4DF7BCF430

P5875

Q33291387-0BD77D7D-44C8-48F3-97EC-67C9D8E0A9C0

P698

Q33291387-119964F8-8894-43B1-BB77-309204CE0985

P356

J.GIE.2006.12.037

P1433

Gastrointestinal Endoscopy

P1476

Five-year efficacy and safety ...... arrett's high-grade dysplasia.

@en

P2093

Bergein F Overholt

http://www.w3.org/2001/XMLSchema#string

Charles J Lightdale

http://www.w3.org/2001/XMLSchema#string

Hector R Nava

http://www.w3.org/2001/XMLSchema#string

Hugh Barr

http://www.w3.org/2001/XMLSchema#string

International Photodynamic Group for High-Grade Dysplasia in Barrett's Esophagus

http://www.w3.org/2001/XMLSchema#string

J Steven Burdick

http://www.w3.org/2001/XMLSchema#string

Kenneth K Wang

http://www.w3.org/2001/XMLSchema#string

Marcos Pedrosa

http://www.w3.org/2001/XMLSchema#string

Mary P Bronner

http://www.w3.org/2001/XMLSchema#string

Michael Grace

http://www.w3.org/2001/XMLSchema#string

P304

460-468

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.GIE.2006.12.037

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P577

2007-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6196011

http://www.w3.org/2001/XMLSchema#string

P698

17643436

http://www.w3.org/2001/XMLSchema#string